Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy
Related Posts
Yu J, Yang Y, Gu Z, Shi M, La Cava A, Liu A. CAR immunotherapy in autoimmune diseases: promises and challenges. Front Immunol. 2024 Oct[...]
Baghdadi JD, Wessel M, Dubberke ER, Lydecker A, Claeys KC, Alonso C, Coffey KC, Durkin M, Gonzales-Luna AJ, Guh AY, Kwon JH, Martin E, Mehrotra[...]
Juakiem WY, Singh K, Ofosu A, Ramai D, Persaud A, Tabibian JH, Rodrigues-Pinto E, Girotra M, Barakat MT. Tertiary Care Center Trends in Colonic Stent[...]